Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Proteinuria in Kidney Transplant Recipients
TCTR20240406005Phase 3Unknown
- Sponsor
- King Chulalongkorn Memorial Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of empagliflozin in proteinuria and Kidney allograft status (RTx) (2 arms), sponsored by King Chulalongkorn Memorial Hospital. Primary endpoint: Change in proteinuria. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
proteinuriaKidney allograft status (RTx)
Beyond the preview
Go deeper on TCTR20240406005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240406005.